Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.37 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 10/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20470739 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16219012 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16750122 | 0.89 | VNN1 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13751427 | 0.88 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17177185 | 0.83 | CHRNB2 (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13819989 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27906724 | 0.79 | HRH3 (0.35) | CNR2VNN1 | |
| SCHEMBL25005213 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL5020032 | 0.78 | DPP4 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL17172991 | 0.78 | CHRNB2 (0.36) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-10246429-B2 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | CHRNB2 121/4885CHRNA3 139/4885CHRNA4 87/4885 |
| US-10246429-B2 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | CHRNB2 121/4885CHRNA3 139/4885CHRNA4 87/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | CHRNB2 4548/4885CHRNA3 4280/4885CHRNA4 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.